The microRNA-375 as a potentially promising biomarker to predict the prognosis of patients with head and neck or esophageal squamous cell carcinoma: a meta-analysis

  • Peng Wang
  • LiangLiang Xu
  • Lian Li
  • ShengSheng Ren
  • JianWei Tang
  • Ming ZhangEmail author
  • MingQing XuEmail author
Review Article



The prognostic value of microRNA-375 (miR-375) expression in squamous cell carcinoma (SCC) had been reported in the previous studies; however, the results remain inconsistent. This study was performed to investigate the prognostic significance of miR-375 expression in SCC based on all eligible evidences.


Relevant studies were identified by searching PubMed, Embace, Medline, Cochrane Library, and China Biology Medicine disk. Survival outcome including overall survival (OS) and other survival outcomes were used as the primary endpoint to evaluate the prognostic outcome of patients with SCC. All statistical analyses were performed in RevMan software version 5.3 and STATA software version 14.1. Furthermore, the quality of included studies was assessed by The Newcastle–Ottawa Scale.


In total, 13 studies, including 1340 patients, met the inclusion criteria for our meta-analysis. The pooled analysis results indicated that downregulation of miR-375 significantly predicted poor OS (HR 1.58, 95% CI 1.34–1.88, P < 0.001). Downregulated miR-375 was also correlated with the other survival outcomes. Subgroup analysis based on tumor type found that lower expression of miR-375 was significantly related with poor OS in patients with esophageal squamous cell carcinoma (ESCC) (HR 1.58, 95% CI 1.29–1.94, P < 0.001) and head and neck squamous cell carcinoma (HNSCC) (HR 1.59, 95% CI 1.16–2.18, P = 0.004).


This meta-analysis demonstrated that the downexpression of miR-375 was significantly correlated with poor OS in patients with SCCs and indicated the potential clinical use of miR-375 as a molecular biomarker, particularly in assessing prognosis for patients with ESCC and HNSCC.


MicroRNA-375 Squamous cell carcinoma Prognosis 



All sources of funding of the study should be disclosed. Please clearly indicate grants that you have received in support of your research work. Clearly state if you received funds for covering the costs to publish in open access.

Author contributions

PW and LX designed the study under the supervision of MX and MZ. PW and LX performed the literature search and evaluated their eligibility independently. PW, LX, LL, and SR extracted and analyzed the data. JT prepared the initial report. PW wrote the paper, and MZ edited the manuscript.


This study was supported by the grants of National Natural Science Foundation of China (no. 71673193), the Key Technology Research and Development Program of the Sichuan Province (2015SZ0131 and 2017FZ0082), and the Natural Science Foundation for Young Scientists of Gansu Province and the Science and Technology Planning Project of Gansu Province (Grant no. 18JR3RA058).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90Google Scholar
  2. 2.
    NCI Dictionary of Cancer Terms. National Cancer Institute. Retrieved 9 Nov 2016
  3. 3.
    Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917Google Scholar
  4. 4.
    Pennathur A et al (2013) Oesophageal carcinoma. Lancet 381(9864):400–412Google Scholar
  5. 5.
    Tran GD et al (2005) Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 113(3):456–463Google Scholar
  6. 6.
    Ruol A et al (2009) Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. Arch Surg 144(3):247–254 (discussion 254) Google Scholar
  7. 7.
    Srivastava VK et al (2014) Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev 15(7):3261–3265Google Scholar
  8. 8.
    Gugic J, Strojan P (2012) Squamous cell carcinoma of the head and neck in the elderly. Rep Pract Oncol Radiother 18(1):16–25Google Scholar
  9. 9.
    Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536):576–582Google Scholar
  10. 10.
    Gonzalez Ferreira JA et al (2015) Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: review of the literature. Rep Pract Oncol Radiother 20(5):328–339Google Scholar
  11. 11.
    Komatsu S et al (2012) Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther 12(Suppl 1):S53–S59Google Scholar
  12. 12.
    Costello E, Greenhalf W, Neoptolemos JP (2012) New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9(8):435–444Google Scholar
  13. 13.
    Du Y et al (2013) Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation. Cancer Biother Radiopharm 28(5):361–369Google Scholar
  14. 14.
    Gao W et al (2018) Promoter methylation-regulated miR-145-5p inhibits laryngeal squamous cell carcinoma progression by targeting FSCN1. Mol Ther 27:1–2Google Scholar
  15. 15.
    Meng L et al (2018) Tumor suppressive miR-6775-3p inhibits ESCC progression through forming a positive feedback loop with p53 via MAGE-A family proteins. Cell Death Dis 9(11):1057Google Scholar
  16. 16.
    Lamperska KM et al (2016) Unpredictable changes of selected miRNA in expression profile of HNSCC. Cancer Biomark 16(1):55–64Google Scholar
  17. 17.
    Marioni G et al (2016) miR-19a and SOCS-1 expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma. J Clin Pathol 69(5):415–421Google Scholar
  18. 18.
    Zhao H et al (2018) MiR-543 promotes migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells by targeting phospholipase A2 group IVA. Cell Physiol Biochem 48(4):1595–1604Google Scholar
  19. 19.
    Avissar M et al (2009) MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 15(8):2850–2855Google Scholar
  20. 20.
    Hui AB et al (2011) Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. Clin Cancer Res 17(24):7539–7550Google Scholar
  21. 21.
    Harris T et al (2012) Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 180(3):917–928Google Scholar
  22. 22.
    Kinoshita T et al (2012) The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways. J Hum Genet 57(9):556–563Google Scholar
  23. 23.
    Yan JW, Lin JS, He XX (2014) The emerging role of miR-375 in cancer. Int J Cancer 135(5):1011–1018Google Scholar
  24. 24.
    He XX et al (2012) MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 31(28):3357–3369Google Scholar
  25. 25.
    Ding L et al (2010) MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20(7):784–793Google Scholar
  26. 26.
    Mathe EA et al (2009) MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 15(19):6192–6200Google Scholar
  27. 27.
    Chang C et al (2012) Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett 531(2):204–208Google Scholar
  28. 28.
    Li X, Lin R, Li J (2011) Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer. Dig Dis Sci 56(10):2849–2856Google Scholar
  29. 29.
    Shao Y et al (2014) Prognostic significance of microRNA-375 downregulation in solid tumors: a meta-analysis. Dis Markers 2014:626185Google Scholar
  30. 30.
    Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012Google Scholar
  31. 31.
    Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605Google Scholar
  32. 32.
    Zhang B et al (2017) MicroRNA-375 inhibits growth and enhances radiosensitivity in oral squamous cell carcinoma by targeting insulin like growth factor 1 receptor. Cell Physiol Biochem 42(5):2105–2117Google Scholar
  33. 33.
    He Y et al (2017) Evaluation of miR-21 and miR-375 as prognostic biomarkers in oesophageal cancer in high-risk areas in China. Clin Exp Metastasis 34(1):73–84Google Scholar
  34. 34.
    Hudcova K et al (2016) Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers. Tumour Biol 37(9):12627–12633Google Scholar
  35. 35.
    Lv H et al (2016) Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication. Am J Transl Res 8(7):3288–3298Google Scholar
  36. 36.
    Li BX et al (2015) Circulating microRNAs in esophageal squamous cell carcinoma: association with locoregional staging and survival. Int J Clin Exp Med 8(5):7241–7250Google Scholar
  37. 37.
    Winther M et al (2015) Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer. Acta Oncol 54(9):1582–1591Google Scholar
  38. 38.
    Hu A et al (2014) miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival. Am J Transl Res 6(5):604–613Google Scholar
  39. 39.
    Jia L et al (2015) miR-375 inhibits cell growth and correlates with clinical outcomes in tongue squamous cell carcinoma. Oncol Rep 33(4):2061–2071Google Scholar
  40. 40.
    Wu C et al (2014) Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep 41(3):1257–1266Google Scholar
  41. 41.
    Li J et al (2013) Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One 8(1):e53582Google Scholar
  42. 42.
    Kong KL et al (2012) MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 61(1):33–42Google Scholar
  43. 43.
    Lian S et al (2016) MicroRNA-375 functions as a tumor-suppressor gene in gastric cancer by targeting recepteur d’origine nantais. Int J Mol Sci 17(10):1–2Google Scholar
  44. 44.
    Cui F et al (2016) miR-375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes. Oncol Rep 36(1):487–493Google Scholar
  45. 45.
    Osako Y et al (2016) Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. Int J Oncol 49(6):2255–2264Google Scholar
  46. 46.
    Jung HM, Benarroch Y, Chan EK (2015) Anti-cancer drugs reactivate tumor suppressor miR-375 expression in tongue cancer cells. J Cell Biochem 116(5):836–843Google Scholar
  47. 47.
    Jung HM et al (2013) Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA–mRNA interactions. Mol Biol Cell 24(11):1638–1648 (s1-7) Google Scholar
  48. 48.
    Hu C et al (2017) MicroRNA-375 suppresses esophageal cancer cell growth and invasion by repressing metadherin expression. Oncol Lett 13(6):4769–4775Google Scholar
  49. 49.
    Elshafei A et al (2017) The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: an Egyptian study. Tumour Biol 39(6):1010428317705765Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Liver SurgeryWest China Hospital, Sichuan UniversityChengduChina
  2. 2.Department of General SurgeryMianzhu Hospital of West China Hospital, Sichuan UniversityMianzhuChina

Personalised recommendations